Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
The Ayala Pharmaceuticals, Inc. (ADXS) news stream captures the company’s evolution as a clinical-stage oncology developer focused on small molecule therapeutics and related platforms for rare tumors and aggressive cancers. Company announcements highlight clinical progress, strategic transactions, and regulatory milestones that shape the outlook for the ADXS symbol on the OTCQX market.
News items include detailed updates on AL102, Ayala’s investigational oral gamma secretase inhibitor for desmoid tumors, and the pivotal RINGSIDE Phase 2/3 trial. Releases discuss Phase 2 efficacy and safety data, the design of the Phase 3 registration segment, and U.S. FDA designations such as Fast Track and Orphan Drug status. Additional coverage describes the integration of aspacytarabine (BST-236), a novel anti-metabolite for unfit acute myeloid leukemia (AML), into Ayala’s pipeline following its merger with Biosight Ltd.
Investors and observers can also follow corporate and asset-level transactions through this news feed. Ayala has reported a definitive asset purchase agreement with Immunome, Inc. to acquire AL102 and AL101, and an asset purchase agreement with OS Therapies, Inc. to acquire its listeria monocytogenes-based immuno-oncology programs and related intellectual property assets, including lung and prostate cancer programs. Another key disclosure is Ayala’s Form 15 filing to deregister its common stock and suspend SEC reporting obligations.
By reviewing Ayala’s news, readers can see how the ADXS story has combined oncology drug development, mergers, and asset sales. The feed is useful for tracking clinical milestones in desmoid tumors and AML, understanding which external companies are now advancing former Ayala assets, and monitoring structural changes such as the merger with Biosight and the transition away from SEC periodic reporting. Bookmarking this page helps users quickly locate historical press releases and transaction announcements related to Ayala Pharmaceuticals and the ADXS ticker.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ayala Pharmaceuticals announced a poster presentation at the 2023 ASCO Annual Meeting, showcasing updated results from the Phase 2 portion of the RINGSIDE study evaluating AL102 for desmoid tumors. The presentation will take place on June 3, 2023, featuring findings from a clinical trial aimed at treating rare connective tissue tumors. The session will be led by Mrinal M. Gounder from the Memorial Sloan Kettering Cancer Center. This study is part of a larger Phase 2/3 trial assessing AL102’s efficacy on desmoid tumors, with a global patient enrollment strategy. Desmoid tumors are rare, with no FDA-approved systemic therapies currently available for challenging cases. AL102 is an investigational therapy designed to inhibit Notch signaling pathways.
Ayala Pharmaceuticals (OTCQX: ADXS) announced positive interim results from its Phase 2/3 RINGSIDE study for AL102, an investigational drug for desmoid tumors. The Independent Data Monitoring Committee (IDMC) recommended continuing the study without modifications, allowing for global patient enrollment in Phase 3. The primary endpoint is progression-free survival (PFS), with key secondary measures including objective response rate (ORR). The company plans to present updated Phase 2 data at a medical meeting in 2023. AL102 aims to address an urgent medical need as no FDA-approved systemic therapies currently exist for progressive desmoid tumors.
Ayala Pharmaceuticals, previously Advaxis Inc., reported its fiscal 2022 results, with revenues dropping to $250,000 from $3.2 million in 2021. The company closed its merger with Old Ayala in January 2023. As of October 31, 2022, cash and cash equivalents stood at $25.2 million. The net loss for the year was approximately $14.4 million, improving from a $17.9 million loss in 2021. Key priorities include advancing the RINGSIDE study of AL102 for desmoid tumors and gaining clarity on the development path of AL101 in recurrent adenoid cystic carcinoma. AL102 received Fast Track designation from the FDA, enhancing its development prospects.
Advaxis announced the completion of its merger with Ayala Pharmaceuticals, effective January 19, 2023. The combined entity will operate under the name Ayala Pharmaceuticals, primarily focused on the development of AL102 for treating desmoid tumors. Advaxis will retain its stock symbol ADXS on OTC, with plans to uplist to Nasdaq, though success is not guaranteed. The management team includes Kenneth Berlin as CEO and a board comprising experienced members from both companies. The merger aims to enhance development capabilities for oncology therapeutics, particularly targeting rare cancers.